Hormones (Athens). 2016 Jan-Mar;15(1):8-14. doi: 10.14310/horm.2002.1659.
Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Achimastos A1, Alexandrides T2, Alexopoulos D3, Athyros V4, Bargiota A5, Bilianou E6, Chrysochoou C7, Drogari E8, Elisaf M9, Ganotakis E10, Goudevenos I11, Ioannidis I12, Kolovou G13, Kotsis V14, Lekakis I15, Liberopoulos E16, Melidonis A17, Nikolaou V18, Ntaios G19, Papanas N20, Pappas S21, Pitsavos C22, Rallidis L23, Richter D24, Skoumas I25, Tentolouris N26, Tousoulis D15, Tselepis A27, Tsioufis K28, Tziakas D29, Tziomalos K30, Vardas P31, Vlachopoulos C32, Vlahakos D33.
- [Indexed for MEDLINE]
From Guideline Database
This database contains updated guidelines, policies and recommendations on genomic research and practice, as provided by professional organizations, federal advisory groups, expert panels and policy groups.
- Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Published 2016 (Expert panel)
- Spanish guidelines for the management of autosomal dominant polycystic kidney disease.
Published 2014 (Spanish Working Group on Inherited Kidney Disease)